Ajay Major, MD, MBA
@majorajay.bsky.social did:plc:plgt5bqnko7dwhzi2436ipuf
Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky
Bluesky’a katılma tarihi:
- Takipçi
- 588
- Takip edilen
- 252
- Post
- 531
- Sıralamaya girdiği gün
- 0
Özet
Ajay Major, MD, MBA (@majorajay.bsky.social), 11 Kasım 2024 tarihinde katılan bir Bluesky kullanıcısı. 588 takipçisi var, 252 hesabı takip ediyor ve 531 post paylaştı.
Sıralama geçmişi
Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.
Bu hesap henüz günlük sıralamaya girmedi.
Son beğendiği postlar
Bluesky ağındaki herkese açık beğeniler.
Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social. Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵 doi.org/10.1016/j.bn...
Postu gösterSelf-promotion. news.cuanschutz.edu/cancer-cente...
Postu gösterJamie Studts, PhD, leads with earnestness, collaboration, and deep respect for community voice — encouraging researchers to pursue what they’re passionate about while grounding science in real-world impact. Full interview: youtu.be/RihtmBmGlIk
Postu gösterCAR T-cell therapy has revolutionized treatment of stubborn cancers. Now, a groundbreaking study from @cucancercenter.bsky.social researchers addresses “a huge unanswered gap” in how CAR T-cell therapy impacts patients over two years. @cuanschutz.bsky.social @majorajay.bsky.social #cucityofhealth
Postu gösterIn a new study, Ajay Major (@majorajay.bsky.social), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: https://bit.ly/3UzIYxF
Postu göster
Blokladığı hesaplar
Bluesky’da bloklar herkese açık kayıtlardır.